Real world evidence study to assess incidence, treatment patterns, clinical outcomes, and health care resource utilization in early-stage, high-risk HER2-negative breast cancer in Alberta, Canada

In a retrospective longitudinal cohort study, researchers evaluated incidence, treatment, and survival data from patients in with high-risk HER2- early breast cancer in Alberta, Canada. They found that overall survival was significantly worse among patients who were older, had grade 3 histology, had stage III disease, or had nodal involvement, which indicates some unmet clinical needs.